BPC-157 has a molecular weight of approximately 1,419 Da on the larger end for nasal mucosal absorption which may constrain bioavailability compared to smaller peptides like Semax (which weighs 604 Da and is specifically designed for nasal delivery).8 Who nasal delivery may be relevant for (research context): Neurological or brain-adjacent applications Patients for whom injection is contraindicated Situations requiring rapid onset with non-invasive administration Research protocols studying nose-to-brain peptide pathways What to be realistic about: No peer-reviewed human trials on intranasal BPC-157 exist as of 2026 Nasal absorption of BPC-157 is less predictable than for smaller peptides Dosing standardisation for nasal BPC-157 is not established Consult a licensed provider before considering this route Peptide Delivery Method Comparison Table How to Choose the Right BPC-157 Delivery Method for Your Goal Matching the delivery method to the clinical goal is the single most important decision in BPC-157 therapy
The receptor profiles are different (dual versus triple agonist), the potency per milligram is different, and the side effect profiles are different
Semax is a Russian-developed neuropeptide available as a nasal spray or injection that has been studied for focus, mental performance, and neurological resilience
Storing lyophilized powder at -80 C can extend stability further for particularly sensitive sequences
Types of B12 Shots Understanding the available types is crucial when choosing the right B12 shot
This very large, diverse group of compounds can also be referred to as synthetic cannabinoid receptor agonists
